[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-189424-105":53,"doc-detail-189424-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","alnylam-q3-2025-earnings-appendix-gaap-to-non-gaap-reconciliation","Alnylam-q3-2025 Earnings Appendix - GAAP与非GAAP对账表","","Appendix provides GAAP to non-GAAP reconciliations for selected financial measures for Alnylam Pharmaceuticals, Inc., covering research and development expenses, selling, general and administrative expenses, operating income (loss), and net income (loss). Adjustments focus on stock-based compensation and related reconciling items such as marketable equity securities impacts, convertible debt losses, and income tax effects. The appendix also includes constant-currency analysis for product revenue growth metrics, showing reported growth, foreign currency translation impact, and growth at constant currency for total TTR, total Rare, net product revenue, and total revenue.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/alnylam-q3-2025-earnings-appendix-gaap-to-non-gaap-reconciliation/189424/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/alnylam-q3-2025-earnings-appendix-gaap-to-non-gaap-reconciliation/189424.png","ImageObject",442,249,{"name":88,"@type":89},"wps_ap_test_251126_0180","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-09-28","2026-09-03",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",8,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What adjustments are used to reconcile GAAP research and development expenses to non-GAAP?","Question",{"text":109,"@type":110},"The reconciliation subtracts stock-based compensation expenses from GAAP research and development expenses to arrive at non-GAAP research and development expenses.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"How is GAAP selling, general and administrative expense converted to non-GAAP?",{"text":114,"@type":110},"The appendix deducts stock-based compensation expenses from GAAP selling, general and administrative expenses to produce non-GAAP selling, general and administrative expenses.",{"name":116,"@type":107,"acceptedAnswer":117},"What does the constant-currency section measure and how is it derived?",{"text":118,"@type":110},"It shows product revenue and growth metrics by starting with reported growth, adjusting for the impact of foreign currency translation, and then presenting the resulting growth at constant currency for multiple revenue categories.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},189424,1788396729,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":76,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":126,"read_time":9},8796095027276,"https://avatar.qwps.com/avatar/d3BzX2FwX3Rlc3RfMjUxMTI2XzAxODA=","Appendix  \n|I  \nAlnylam Pharmaceuticals,Inc.  \n# Reconciliation of Selected GAAP Measures to Non-GAAP Measures(In thousands)\n\n  Three Months Ended    \nSeptember 30,  \n  2025    \n  2024    \nReconciliation of GAAP to Non-GAAP Research and development expenses:GAAPResearch and development expenses358,814270,926Less:Stock-based compensation expenses                         (48,725)   (19,794)Non-GAAPResearch and development expenses                    310,089 $251,132Reconciliation of GAAPto Non-GAAP Selling,general and administrative expenses:GAAP Selling.general and administrative expensesS322,076 $220,993Less:Stock-based compensation expenses   (59,486)   (26,010)Non-GAAP Selling,general and administrative expenses            S262,590   194,983Reconciliation of GAAPto Non-GAAPIncome(loss)from operations:  \n\n| GAAPIncome(loss)from operations   | S  \u003Cbr>367,982    | (76,905)  \u003Cbr>$   |\n| --- | --- | --- |\n| Add:Stock-based compensation expenses   | 108,211   | 45,804   |\n| Non-GAAPOperating income (loss)   | 476,193  \u003Cbr>$   | S  \u003Cbr>(31,101)   |\n| Reconciliation of GAAPto Non-GAAPNet income(loss):   |  |  |\n| GAAPNet income(loss)   | S  \u003Cbr>251,084    | $  \u003Cbr>(111,570)   |\n| Add:Stock-based compensation expenses   | 108,211   | 45,804   |\n| Add:Realized and unrealized loss on marketable equity securities   | 一   | 1,567   |\n| Add:Loss related to convertible debt   | 39,146   | 一   |\n| Less:Income tax effect of GAAP to non-GAAP reconciling items   | (2,261)   |  |\n| Non-GAAPNet income(loss)   | 396,180  \u003Cbr>S(   | (64,199)  \u003Cbr>$   |\n\n|  \nAlnylam Pharmaceuticals,Inc.  \n# Reconciliation of Product Revenue and Growth at Constant Currency\n\n  September 30,2025    Three Months Ended  Total TTR net product revenue growth,as reported135%Add:Impact of foreign currency translation        (4)Total TTR net product revenue growth at constant currency131%Total Rare net product revenue growth,as reportedAdd:Impact of foreign currency translation                                                  (3)Total Rare net product revenue growth at constant currency11%Total net product revenue growth,as reported103%Add:Impact of foreign currency translation                                                      (4)Total net product revenue growth at constant currency             99%Total revenue growth,as reported149%Add:Impact of foreign currency translation(2)Total revenue growth at constant currency147%  \n14%","cbCaigz6J2vrikin","https://ap.wps.com/l/cbCaigz6J2vrikin","pdf",133567,"English","# Reconciliation of Selected GAAP Measures to Non-GAAP Measures\n## Reconciliation of GAAP to Non-GAAP Research and development expenses\n## Reconciliation of GAAP to Non-GAAP Selling, general and administrative expenses\n## Reconciliation of GAAP to Non-GAAP Income (loss) from operations\n## Reconciliation of GAAP to Non-GAAP Net income (loss)\n# Reconciliation of Product Revenue and Growth at Constant Currency","[{\"question\":\"What adjustments are used to reconcile GAAP research and development expenses to non-GAAP?\",\"answer\":\"The reconciliation subtracts stock-based compensation expenses from GAAP research and development expenses to arrive at non-GAAP research and development expenses.\"},{\"question\":\"How is GAAP selling, general and administrative expense converted to non-GAAP?\",\"answer\":\"The appendix deducts stock-based compensation expenses from GAAP selling, general and administrative expenses to produce non-GAAP selling, general and administrative expenses.\"},{\"question\":\"What does the constant-currency section measure and how is it derived?\",\"answer\":\"It shows product revenue and growth metrics by starting with reported growth, adjusting for the impact of foreign currency translation, and then presenting the resulting growth at constant currency for multiple revenue categories.\"}]","Alnylam-q3-2025 Earnings Appendix - GAAP与非GAAP对账表 | PDF"]